# Celltrion
 (stock symbol: 068270.KS) Logo in transparent PNG format

## Celltrion
 Logo large

### Celltrion
 Logo large Download PNG (37.34 KB)

![Celltrion
 Logo large Download PNG (37.34 KB)](/img/orig/068270.KS_BIG-a5bc7dba.png)

## Celltrion
 Logo icon format

### Celltrion
 Logo icon format Download PNG (75.89 KB)

![Celltrion
 Logo icon format Download PNG (75.89 KB)](/img/orig/068270.KS-65131e23.png)

## About Celltrion


Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.

1. Website domain: celltrion.com
2. Marketcap: $18.58 Billion USD


## Categories
- [x] ðŸ‡°ðŸ‡· South Korea
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
